| Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BEDFORD, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on May 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 5,000 shares of common stock at a per share exercise price of $14.46, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to two newly hired non-executive employees. The grants were made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, were approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), were made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation. |
globenewswire.com |
2025-05-12 21:00:00 |
Czytaj oryginał (ang.) |
| Anika Therapeutics, Inc. (ANIK) Q1 2025 Earnings Call Transcript |
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Matt Hall - Director, Corporate Development & Investor Relations Cheryl Blanchard - President & Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer & Chief Operating Officer Conference Call Participants Anderson Schock - B. Riley Securities Mike Petusky - Barrington Research Jim Sidoti - Sidoti & Company. |
seekingalpha.com |
2025-05-09 15:51:37 |
Czytaj oryginał (ang.) |
| Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates |
Anika Therapeutics (ANIK) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.09. This compares to loss of $0.31 per share a year ago. |
zacks.com |
2025-05-09 13:35:35 |
Czytaj oryginał (ang.) |
| Anika Reports First Quarter 2025 Financial Results |
First Quarter 2025 Commercial Channel revenue up 18% Integrity ™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for the first quarter ended March 31, 2025. |
globenewswire.com |
2025-05-09 11:05:00 |
Czytaj oryginał (ang.) |
| Anika to Participate in the Sidoti Virtual Investor Conference |
BEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that management will participate in the Sidoti Virtual Investor Conference on Wednesday, May 21, 2025. Anika will host a virtual presentation with Q&A starting at 1:00pm ET. |
globenewswire.com |
2025-05-07 20:01:00 |
Czytaj oryginał (ang.) |
| Is the Options Market Predicting a Spike in Anika Therapeutics Stock? |
Investors need to pay close attention to ANIK stock based on the movements in the options market lately. |
zacks.com |
2025-05-05 14:30:52 |
Czytaj oryginał (ang.) |
| Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025 |
BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2025 financial results before the opening of the market on Friday, May 9, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. |
globenewswire.com |
2025-04-25 13:00:00 |
Czytaj oryginał (ang.) |
| Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BEDFORD, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the Osteoarthritis (“OA”) Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced that on April 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 3,800 shares of common stock at a per share exercise price of $15.03, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation. |
globenewswire.com |
2025-04-07 21:00:00 |
Czytaj oryginał (ang.) |
| Anika Therapeutics, Inc. (ANIK) Q4 2024 Earnings Call Transcript |
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Matt Hall - Director, Corporate Development & Investor Relations Cheryl Blanchard - President & Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Jim Sidoti - Sidoti & Co. Mike Petusky - Barrington Research Operator Good morning, ladies and gentlemen, and welcome to Anika's Fourth Quarter and Year End Earnings Conference Call. At this time, all lines are in listen-only mode. |
seekingalpha.com |
2025-03-12 19:55:57 |
Czytaj oryginał (ang.) |
| Anika Reports Fourth Quarter and Full Year 2024 Financial Results |
Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Commercial Channel growth and 2024 results Key Regulatory and Clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Strategic Sale of Parcus Medical complete; resources refocused on programs positioned to generate significantly higher returns BEDFORD, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the Osteoarthritis ("OA") Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced financial results for the fourth quarter and full year ended December 31, 2024. |
globenewswire.com |
2025-03-12 18:05:00 |
Czytaj oryginał (ang.) |
| Anika Completes Divestiture of Parcus Medical |
Execution of Previously Announced Plan Sharpens Focus on Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio Execution of Previously Announced Plan Sharpens Focus on Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio |
globenewswire.com |
2025-03-07 08:00:00 |
Czytaj oryginał (ang.) |
| Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025 |
BEDFORD, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2024 financial results after the close of the market on Wednesday, March 12, 2025 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights. |
globenewswire.com |
2025-02-26 10:00:00 |
Czytaj oryginał (ang.) |
| Anika To Present at the Canaccord Genuity 2025 Musculoskeletal Conference |
BEDFORD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego on Monday, March 10, 2025 at 2:30pm PT / 5:30pm ET. Management will also participate in one-on-one investor meetings throughout the event. |
globenewswire.com |
2025-02-25 10:00:00 |
Czytaj oryginał (ang.) |
| Anika To Participate in 43rd Annual J.P. Morgan Healthcare Conference |
BEDFORD, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET. Management will also participate in one-on-one investor meetings throughout the event. |
globenewswire.com |
2024-12-23 18:01:00 |
Czytaj oryginał (ang.) |
| Anika To Participate in December 2024 Investor Conferences |
BEDFORD, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that senior management will participate in the following upcoming conferences. |
globenewswire.com |
2024-11-22 18:16:00 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for November 11th |
AMRK, ANIK and ALG have been added to the Zacks Rank #5 (Strong Sell) List on November 11, 2024. |
zacks.com |
2024-11-11 04:31:07 |
Czytaj oryginał (ang.) |
| Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript |
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Matt Hall - Director, Corporate Development and IR Cheryl Blanchard - President and CEO Steve Griffin - EVP, CFO and Treasurer Conference Call Participants Jim Sidoti - Sidoti & Co. Mike Petusky - Barrington Research Operator Good morning, ladies and gentlemen, and welcome to Anika's Third Quarter Earnings Conference Call. [Operator Instructions]. |
seekingalpha.com |
2024-11-02 23:41:26 |
Czytaj oryginał (ang.) |
| Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates |
Anika Therapeutics (ANIK) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of $0.30. This compares to loss of $0.45 per share a year ago. |
zacks.com |
2024-10-31 11:25:23 |
Czytaj oryginał (ang.) |
| Anika Reports Third Quarter 2024 Financial Results |
Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds |
globenewswire.com |
2024-10-31 09:05:00 |
Czytaj oryginał (ang.) |
| Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical |
Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations and Enhance Growth Profile Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations and Enhance Growth Profile |
globenewswire.com |
2024-10-31 09:00:00 |
Czytaj oryginał (ang.) |
| Anika Announces Third Quarter 2024 Results Conference Call Date |
BEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2024 financial results before the opening of the market on Thursday, October 31, 2024, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. |
globenewswire.com |
2024-10-17 20:01:00 |
Czytaj oryginał (ang.) |
| Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BEDFORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on October 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 6,350 shares of common stock at a per share exercise price of $24.27, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation. |
globenewswire.com |
2024-10-04 20:01:00 |
Czytaj oryginał (ang.) |
| Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BEDFORD, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on September 3, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.15, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation. |
globenewswire.com |
2024-09-09 20:45:00 |
Czytaj oryginał (ang.) |
| Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BEDFORD, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on August 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 8,850 shares of common stock at a per share exercise price of $26.29, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to two newly hired non-executive employees. The grants were made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, were approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), were made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation. |
globenewswire.com |
2024-08-15 20:01:00 |
Czytaj oryginał (ang.) |
| Anika Therapeutics, Inc (ANIK) Q2 2024 Earnings Call Transcript |
Anika Therapeutics, Inc (NASDAQ:ANIK ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations Cheryl Blanchard - President and Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Jim Sidoti - Sidoti & Company Harrison Parsons - Stephens Mike Petusky - Barrington Research Operator Good afternoon, ladies and gentlemen, and welcome to Anika's Second Quarter 2024 Earnings Conference Call. [Operator Instructions] I will now turn the call over to Mark Namaroff, Vice President, Investor Relations, ESG and Corp. Communications. |
seekingalpha.com |
2024-08-11 05:49:01 |
Czytaj oryginał (ang.) |
| Anika Therapeutics (ANIK) Q2 Earnings Lag Estimates |
Anika Therapeutics (ANIK) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.19 per share a year ago. |
zacks.com |
2024-08-08 23:36:54 |
Czytaj oryginał (ang.) |
| Anika Reports Second Quarter 2024 Financial Results |
Expanded Regenerative Solutions portfolio with full market release of the Integrity™ Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating significant market demand |
globenewswire.com |
2024-08-08 20:05:00 |
Czytaj oryginał (ang.) |
| Anika to Participate in the Sidoti Virtual Investor Conference |
BEDFORD, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the Sidoti Virtual Investor Conference on Thursday, August 15, 2024. Anika will host a virtual presentation with Q&A starting at 11:30am ET. |
globenewswire.com |
2024-08-05 20:01:00 |
Czytaj oryginał (ang.) |
| Anika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024 |
BEDFORD, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2024 financial results after the close of the market on Thursday, August 8, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights. |
globenewswire.com |
2024-07-25 13:00:00 |
Czytaj oryginał (ang.) |
| Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BEDFORD, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on July 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.85, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation. |
globenewswire.com |
2024-07-16 11:19:00 |
Czytaj oryginał (ang.) |
| Anika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs |
Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika's proprietary hyaluronic acid (HA) regenerative portfolio |
globenewswire.com |
2024-07-11 12:30:00 |
Czytaj oryginał (ang.) |
| Orthopedic Regenerative Surgical Products Market Size to Reach USD 6.6 Billion By 2033, at 4.4 CAGR: Insights by Dimension Market Research |
Advancements and Projections in the Orthopedic Regenerative Surgical Products Market: Insights, Trends, Opportunities, and Recent Developments Advancements and Projections in the Orthopedic Regenerative Surgical Products Market: Insights, Trends, Opportunities, and Recent Developments |
globenewswire.com |
2024-07-01 14:35:00 |
Czytaj oryginał (ang.) |
| Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BEDFORD, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on June 3, 2024, Anika granted: (i) non-statutory stock options (“Options”) covering 96,525 shares of common stock at a per share exercise price of $29.35, which equaled 110% of the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, and (ii) restricted stock units (“RSUs”) covering 38,520 shares of common stock, to Stephen Griffin, the Company's recently appointed Executive Vice President, Chief Financial Officer and Treasurer. The grants were made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, were approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), were made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation. |
globenewswire.com |
2024-06-07 20:01:00 |
Czytaj oryginał (ang.) |